Search

Displaying results 1181 - 1190 of 1745 in total
  1. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld.

  2. Drug

    Polysorbate 80

    go.drugbank.com/drugs/DB11063
    ApprovedInvestigational

    Polysorbate, a substance formulated by the reaction of sorbitan fatty acid ester (a nonionic surfactant) with ethylene oxide, is used in many foreign countries, including the U.S. and the EU, where it

  3. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

  4. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).

    Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & D
  5. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.

  6. Drug

    QR-334

    go.drugbank.com/drugs/DB05473
    Experimental

    No pharmaceutical interventions currently exist to treat sialorrhea.

  7. Drug

    Arecoline

    go.drugbank.com/drugs/DB04365
    Experimental

    An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors.

  8. Drug

    Zolazepam

    go.drugbank.com/drugs/DB11555
    ExperimentalVet approved

    It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.

  9. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd

  10. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.